#USA #AI Solutions #Virginia #Appian #PSI CRO

Appian and PSI CRO Form a Groundbreaking Partnership

In a major advancement for the clinical research sector, Appian and PSI CRO have announced a strategic partnership designed to revolutionize the orchestration of clinical trial processes through artificial intelligence. This collaboration marks the introduction of their first joint AI-powered solution, aimed specifically at automating the selection and identification of suitable clinical trial sites across various therapeutic areas and countries.

Revolutionizing Clinical Trial Operations

The newly launched solution is not merely an incremental update, but represents a significant stride towards establishing a comprehensive strategic platform. This platform aims to integrate automation, AI capabilities, and process orchestration to streamline the entirety of clinical trial lifecycles. By combining their respective strengths—Appian's prowess in process automation and PSI CRO's expertise in managing clinical trials—the two companies are setting a new standard for efficiency, transparency, and speed in clinical research.

As the healthcare industry increasingly embraces AI technologies, the efficiency gained from this solution could potentially transform the way clinical trials are planned and executed. The traditional method of site selection is often plagued by the need for extensive coordination among multiple parties. Documentation, approvals, and various activities must be aligned effectively across different regions and therapeutic domains. The Appian and PSI CRO solution seeks to eliminate these bottlenecks by consolidating traditionally manual processes into a seamless digital workflow.

Key Features of the New Solution

One of the standout features of this AI-driven solution is its ability to provide end-to-end transparency throughout the site selection process. Leveraging Appian's advanced platform capabilities recognized in the 2026 Gartner® Magic Quadrant™ for Business Orchestration and Automation Technologies, this new solution is designed to:

• - Identify the best-suited clinical trial sites efficiently.
• - Enhance the speed of decision-making, ensuring timely selection processes.
• - Facilitate real-time insights into the performance of the clinical trial processes.

Moreover, the integration of AI functions allows for a more intelligent processing of information and documents. This not only reduces the manual workload involved but also allows seamless communication between teams across borders. Whether it's steering the flow of tasks or handling exceptions, the AI capabilities incorporated into the solution are set to play a pivotal role in elevating the overall operation of clinical trials.

Foundations for Future Success

The unveiling of this solution signifies just the beginning of a longer-term platform strategy envisioned by both companies. It embodies PSI’s commitment to conducting clinical trials predictably and efficiently, while fully capitalizing on Appian’s automation and AI technologies. As noted by PSI’s Head of Process Improvement, Kirill Soldatov, “This AI-driven site selection solution is an important step in rethinking our operational processes.” This innovative approach aims to significantly reduce the number of trial sites struggling to recruit patients and aims to eliminate delays in patient enrollment which have long plagued clinical trials.

Alexander Motie, Regional Vice President at Appian, emphasized the transformative impact of embedding AI into business processes: “This first joint project showcases the value that AI can generate when integrated into operational workflows. Our strategic partnership is set to create a foundation for further automation and innovation in clinical research.”

Next Steps in Clinical Research

With the launch of this solution, both Appian and PSI CRO have plans to explore additional use cases to extend the AI-driven orchestration capabilities into other phases of clinical trials. Their end goal is clear: to accelerate clinical trials, enhance predictability, and ultimately lower the costs of bringing new medical products to market. As the healthcare landscape continues to evolve, the partnership between these two companies stands to champion the integration of technological advancements into clinical research, leading to faster, safer, and more reliable trials.

The collaboration between Appian and PSI CRO signifies an exciting era in clinical research, one where technology not only complements but transforms traditional practices. Companies in the life sciences sector can leverage such automation to fast-track innovations—an essential move as we navigate the complexities of modern healthcare demands.